FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy

Sebelius report re-states need for vax-making makeover

Free Newsletter

FiercePharma Manufacturing provides must-know news and insight on the hardware and software tools used to automate pharmaceutical manufacturing. Sign up today to receive your FREE "insiders only" weekly pharma manufacturing industry briefing.



Tools

Expect HHS to complete a draft solicitation for vaccine manufacturing and development "centers of innovation" in the coming weeks. Secretary Kathleen Sebelius, staying on message since the beginning of this year, released last week The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs.

The report assesses the government's system to produce medications, vaccines, equipment and supplies for health emergencies. Then it makes recommendations for fixes.

Sebelius said in February that the current limitations of vaccine-manufacturing technology are among the biggest lessons learned from the 2009 H1N1 flu. The current report is the culmination of a fast-track review of the existing "safe but outdated" processes that she initiated then.

Recommendations include development of "agile manufacturing" of medical countermeasures for faster and more effective responses to public health threats. Along these lines, she's looking for manufacturing processes that can be used for multiple medications or vaccines rather than those developed for just one.

She expressed also the need for "a modernized countermeasure production process," spanning the research, development and FDA approval steps of such products. And she finds a need to" upgrade science and regulatory capacity at the FDA" to complement the manufacturing and development upgrades. She promises significant government investment.

- read this article

Related Article:
Sebelius keeps vaccine manufacturing tech in spotlight
HHS: U.S. needs $200M biodefense fund


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:

More stories about vaccine manufacturing   Kathleen Sebelius